ARGX

News Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients

14d ago

News Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB

14d ago

News Belgium stocks higher at close of trade; BEL 20 up 1.37% - Investing.com

14d ago

News Belgium stocks lower at close of trade; BEL 20 down 0.24% By Investing.com - Investing.com

14d ago

News Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates - Zacks Investment Research

14d ago

News Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?

14d ago

News Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday

14d ago

News FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder

14d ago

News Why Is European Drugmaker Argenx Stock Trading Higher On Monday?

14d ago

News Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study

14d ago

News This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story

14d ago

News Jefferies updates Franchise Picks list, adding AMZN, APP, MCD and more

15d ago

News Argenx Eyes Larger Patient Pool Following Expanded FDA Nod For Lead Drug For Neuromuscular Disease

21d ago

News Argenx wins FDA nod to broaden Vyvgart label in myasthenia gravis

23d ago

SEC filing ARGX Reports $1.3B Q1 Sales, 63% YoY Growth, VYVGART PDUFA May 10, 2026, Conference Call 2:30 PM CET

26d ago

News argenx SE GAAP EPS of $5.52 beats by $0.31, revenue of $1.3B misses by $10M

26d ago

SEC filing ARGX Reports $1.2B Revenue, $0.85 EPS, +42% YoY, Launches VYVGART Hytrulo for CIDP, Expands MG Pipeline, ADAPT OCULUS Meets Primary Endpoint, FDA Priority Review for oMG, ADHERE Shows 87.5% Early Benefit in Naïve CIDP, Phase 3 ADAPT SERON Positive Across Serotypes, ADAPT Jr Achie

43d ago

SEC filing ARGX Announces May 6 2026 AGM, Board Changes, Jim Daly Retires, 4 New Directors Appointed

73d ago

SEC filing ARGX Presents VYVGART Phase 3 ADAPT OCULUS Data, ADAPT SERON Results, CIDP Biomarker Insights

88d ago

News Argenx Touts Positive Phase 3 Eye Disease Study Results

96d ago

News Argenx bid for Vyvgart label expansion undergoes FDA priority review

140d ago

News Argenx announces CEO transition

148d ago

News argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients

153d ago

News Denali Therapeutics Announces Board and Executive Leadership Updates

153d ago